Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
The demand for Lipid-Lowering Agents in Tajikistan has been increasing steadily in recent years.
Customer preferences: Tajikistan has a high prevalence of cardiovascular diseases, which has led to an increase in the demand for Lipid-Lowering Agents. Patients are increasingly seeking treatment options that can help manage their cholesterol levels and prevent heart disease.
Trends in the market: The market for Lipid-Lowering Agents in Tajikistan is dominated by statins, which are the most commonly prescribed medications for managing cholesterol levels. However, there is also a growing trend towards the use of natural supplements and alternative therapies for managing cholesterol levels. This is largely due to the perception that natural remedies are safer and have fewer side effects than traditional medications.
Local special circumstances: The healthcare system in Tajikistan is underdeveloped, and access to healthcare is limited in many areas. This has led to a growing demand for over-the-counter medications and natural remedies, as patients often do not have access to prescription drugs.
Underlying macroeconomic factors: Tajikistan is a low-income country with a largely rural population. The economy is heavily dependent on remittances from migrant workers, which has led to high levels of poverty and limited access to healthcare. The government has made efforts to improve healthcare access and quality in recent years, but progress has been slow. As a result, many patients in Tajikistan are turning to alternative therapies and over-the-counter medications to manage their health conditions.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)